Media headlines about Ionis Pharmaceuticals (NASDAQ:IONS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.7892530793322 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment’s analysis:

Shares of Ionis Pharmaceuticals (IONS) traded up $0.67 during midday trading on Friday, reaching $54.60. The company’s stock had a trading volume of 609,286 shares, compared to its average volume of 757,499. Ionis Pharmaceuticals has a 12-month low of $37.26 and a 12-month high of $65.51. The firm has a market capitalization of $6,730.22, a PE ratio of 359.53 and a beta of 2.85. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21.

IONS has been the topic of several recent analyst reports. BMO Capital Markets boosted their price target on Ionis Pharmaceuticals from $67.00 to $69.00 and gave the stock an “outperform” rating in a research note on Monday, August 14th. Laidlaw reiterated a “buy” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, August 14th. Evercore ISI initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 price target on the stock. Barclays initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price target on the stock. Finally, Stifel Nicolaus reiterated a “hold” rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, September 12th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $50.31.

In other Ionis Pharmaceuticals news, CEO Stanley T. Crooke sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $52.00, for a total transaction of $780,000.00. Following the sale, the chief executive officer now owns 43,014 shares in the company, valued at $2,236,728. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. The disclosure for this sale can be found here. Insiders have sold 123,886 shares of company stock worth $7,098,315 in the last 90 days. 2.13% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals (IONS) Earns Daily Media Sentiment Score of 0.18” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/ionis-pharmaceuticals-ions-earns-daily-media-sentiment-score-of-0-18/1754725.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.